{"name":"Astellas Pharma Inc.","slug":"astellas","ticker":"ALPMY","exchange":"OTC","domain":"astellas.com","description":"Astellas Pharma Inc.  is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd.  and Fujisawa Pharmaceutical Co., Ltd. .","hq":"Tokyo, Japan","founded":1992,"employees":"13643","ceo":"Naoki Okamura","sector":"Big Pharma","stockPrice":16.36,"stockChange":-0.02,"stockChangePercent":-0.12,"marketCap":"$29.6B","metrics":{"revenue":2060613976064,"revenueGrowth":10.4,"grossMargin":81,"rdSpend":0,"netIncome":322909995008,"cash":254295998464,"dividendYield":3.11,"peRatio":37.2,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Xtandi","genericName":"enzalutamide","slug":"enzalutamide","revenue":4500000000,"yoyGrowth":0,"percentOfTotal":46.4},{"name":"Padcev","genericName":"AGS-22M6E","slug":"ags-22m6e","revenue":2300000000,"yoyGrowth":0,"percentOfTotal":23.7},{"name":"Prograf","genericName":"TACROLIMUS","slug":"tacrolimus","revenue":1600000000,"yoyGrowth":0,"percentOfTotal":16.5},{"name":"Xospata","genericName":"GILTERITINIB","slug":"gilteritinib","revenue":600000000,"yoyGrowth":0,"percentOfTotal":6.2},{"name":"Evrenzo","genericName":"ROXADUSTAT","slug":"roxadustat","revenue":600000000,"yoyGrowth":0,"percentOfTotal":6.2},{"name":"Vyloy","genericName":"ZOLBETUXIMAB","slug":"zolbetuximab","revenue":100000000,"yoyGrowth":0,"percentOfTotal":1}],"timeline":[{"date":"1964-01-01","label":"Abelcet first approved","drug":"Abelcet","drugSlug":"amphotericin-b","type":"approval","sentiment":"positive"},{"date":"1979-01-01","label":"Cyclocort first approved","drug":"Cyclocort","drugSlug":"amcinonide","type":"approval","sentiment":"positive"},{"date":"1989-01-01","label":"Adenocard first approved","drug":"Adenocard","drugSlug":"adenosine","type":"approval","sentiment":"positive"},{"date":"1994-01-01","label":"Prograf first approved","drug":"Prograf","drugSlug":"tacrolimus","type":"approval","sentiment":"positive"},{"date":"2003-01-01","label":"Amevive first approved","drug":"Amevive","drugSlug":"alefacept","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Vesicare first approved","drug":"Vesicare","drugSlug":"solifenacin","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Xtandi first approved","drug":"Xtandi","drugSlug":"enzalutamide","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Cresemba first approved","drug":"Cresemba","drugSlug":"isavuconazonium","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Xospata first approved","drug":"Xospata","drugSlug":"gilteritinib","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Padcev first approved","drug":"Padcev","drugSlug":"ags-22m6e","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Veozah first approved","drug":"Veozah","drugSlug":"fezolinetant","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Izervay first approved","drug":"Izervay","drugSlug":"avacincaptad-pegol","type":"approval","sentiment":"positive"},{"date":"2024-01-01","label":"Vyloy first approved","drug":"Vyloy","drugSlug":"zolbetuximab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-09-30","label":"Vyloy PHASE3 readout","drug":"Vyloy","drugSlug":"zolbetuximab","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-09-30","label":"Vyloy PHASE3 readout","drug":"Vyloy","drugSlug":"zolbetuximab","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-05-30","label":"Prograf patent expiry (Method of Use)","drug":"Prograf","drugSlug":"tacrolimus","type":"patent_expiry","sentiment":"negative"},{"date":"2028-05-30","label":"Prograf patent expiry (Method of Use)","drug":"Prograf","drugSlug":"tacrolimus","type":"patent_expiry","sentiment":"negative"},{"date":"2028-05-30","label":"Prograf patent expiry (Method of Use)","drug":"Prograf","drugSlug":"tacrolimus","type":"patent_expiry","sentiment":"negative"},{"date":"2028-05-30","label":"Prograf patent expiry (Method of Use)","drug":"Prograf","drugSlug":"tacrolimus","type":"patent_expiry","sentiment":"negative"},{"date":"2028-05-30","label":"Prograf patent expiry (Formulation)","drug":"Prograf","drugSlug":"tacrolimus","type":"patent_expiry","sentiment":"negative"},{"date":"2028-05-30","label":"Prograf patent expiry (Formulation)","drug":"Prograf","drugSlug":"tacrolimus","type":"patent_expiry","sentiment":"negative"},{"date":"2028-05-30","label":"Prograf patent expiry (Formulation)","drug":"Prograf","drugSlug":"tacrolimus","type":"patent_expiry","sentiment":"negative"},{"date":"2028-05-30","label":"Prograf patent expiry (Formulation)","drug":"Prograf","drugSlug":"tacrolimus","type":"patent_expiry","sentiment":"negative"},{"date":"2028-08-30","label":"Prograf patent expiry (Method of Use)","drug":"Prograf","drugSlug":"tacrolimus","type":"patent_expiry","sentiment":"negative"},{"date":"2028-08-30","label":"Prograf patent expiry (Formulation)","drug":"Prograf","drugSlug":"tacrolimus","type":"patent_expiry","sentiment":"negative"},{"date":"2028-09-30","label":"VYLOY Phase 3 readout (Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer)","drug":"VYLOY","drugSlug":"zolbetuximab-clzb","type":"phase3_readout","sentiment":"neutral"},{"date":"2033-09-11","label":"Xtandi patent expiry (Method of Use)","drug":"Xtandi","drugSlug":"enzalutamide","type":"patent_expiry","sentiment":"negative"},{"date":"2033-09-11","label":"Xtandi patent expiry (Method of Use)","drug":"Xtandi","drugSlug":"enzalutamide","type":"patent_expiry","sentiment":"negative"},{"date":"2033-09-11","label":"Xtandi patent expiry (Formulation)","drug":"Xtandi","drugSlug":"enzalutamide","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Xtandi patent cliff ($1.5B at risk)","drug":"Xtandi","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Myrbetriq patent cliff ($1.1B at risk)","drug":"Myrbetriq","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":7500000000,"percentOfTotal":77.3,"drugCount":20,"colorKey":"oncology","drugs":[{"name":"Xtandi","genericName":"enzalutamide","slug":"enzalutamide","indication":"Malignant tumor of prostate","status":"marketed","revenue":4500000000},{"name":"Padcev","genericName":"AGS-22M6E","slug":"ags-22m6e","indication":"Metastatic urothelial carcinoma","status":"marketed","revenue":2300000000},{"name":"Xospata","genericName":"GILTERITINIB","slug":"gilteritinib","indication":"Acute myeloid leukemia, disease","status":"marketed","revenue":600000000},{"name":"Vyloy","genericName":"ZOLBETUXIMAB","slug":"zolbetuximab","indication":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma","status":"marketed","revenue":100000000},{"name":"Xtandi","genericName":"xtandi","slug":"xtandi","indication":"Malignant tumor of prostate","status":"marketed"},{"name":"Enfortumab","genericName":"padcev","slug":"padcev","indication":"Metastatic urothelial carcinoma","status":"marketed"},{"name":"ASP8477","genericName":"ASP8477","slug":"asp8477","indication":"Relapsed or refractory non-Hodgkin lymphoma","status":"phase_2"},{"name":"ASKP1240","genericName":"ASKP1240","slug":"askp1240","indication":"Relapsed or refractory follicular lymphoma","status":"phase_2"},{"name":"ASP0456","genericName":"ASP0456","slug":"asp0456","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"phase_2"},{"name":"ASP1585","genericName":"ASP1585","slug":"asp1585","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"ASP1650","genericName":"ASP1650","slug":"asp1650","indication":"Advanced solid tumors (in combination with checkpoint inhibitors)","status":"phase_2"},{"name":"ASP2215","genericName":"ASP2215","slug":"asp2215","indication":"Non-small cell lung cancer with ALK rearrangement","status":"phase_2"},{"name":"Corticosteroids (Prednisone)","genericName":"Corticosteroids (Prednisone)","slug":"corticosteroids-prednisone","indication":"Rheumatoid arthritis and other autoimmune inflammatory conditions","status":"marketed"},{"name":"Cyclocort","genericName":"AMCINONIDE","slug":"amcinonide","indication":"Atopic dermatitis","status":"marketed"},{"name":"Cyclophosphamide injections","genericName":"Cyclophosphamide injections","slug":"cyclophosphamide-injections","indication":"Lymphomas (Hodgkin and non-Hodgkin)","status":"phase_3"},{"name":"Eligard","genericName":"Eligard","slug":"eligard","indication":"Advanced Prostatic Carcinoma","status":"marketed"},{"name":"Graceptor®","genericName":"Graceptor®","slug":"graceptor","indication":"Treatment of breast cancer","status":"phase_2"},{"name":"LoDAC (Low Dose Cytarabine)","genericName":"LoDAC (Low Dose Cytarabine)","slug":"lodac-low-dose-cytarabine","indication":"Myelodysplastic syndrome (MDS)","status":"phase_3"},{"name":"enfortumab vedotin (EV)","genericName":"enfortumab vedotin (EV)","slug":"enfortumab-vedotin-ev","indication":"Locally advanced or metastatic urothelial cancer","status":"phase_3"},{"name":"methylprednisolone and prednisone","genericName":"methylprednisolone and prednisone","slug":"methylprednisolone-and-prednisone","indication":"Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":1600000000,"percentOfTotal":16.5,"drugCount":17,"colorKey":"immunology","drugs":[{"name":"Prograf","genericName":"TACROLIMUS","slug":"tacrolimus","indication":"Atopic dermatitis","status":"marketed","revenue":1600000000},{"name":"ASP5541","genericName":"ASP5541","slug":"asp5541","indication":"Inflammatory and autoimmune disorders (specific indications under investigation in phase 2)","status":"phase_2"},{"name":"ASP8232","genericName":"ASP8232","slug":"asp8232","indication":"Treatment of autoimmune diseases","status":"phase_2"},{"name":"Amevive","genericName":"ALEFACEPT","slug":"alefacept","indication":"Plaque psoriasis","status":"marketed"},{"name":"FK506E","genericName":"FK506E","slug":"fk506e","indication":"Prevention of organ rejection in transplant recipients","status":"phase_3"},{"name":"Tacrolimus immediate-release formulation","genericName":"Tacrolimus immediate-release formulation","slug":"tacrolimus-immediate-release-formulation","indication":"Organ transplant rejection prophylaxis (kidney, heart, liver)","status":"marketed"},{"name":"Tacrolimus sustained-release capsule","genericName":"Tacrolimus sustained-release capsule","slug":"tacrolimus-sustained-release-capsule","indication":"Prophylaxis of organ rejection in allogeneic kidney, heart, and liver transplant recipients","status":"marketed"},{"name":"ASP1707","genericName":"ASP1707","slug":"asp1707","indication":"Treatment of autoimmune diseases","status":"phase_2"},{"name":"ASP4345","genericName":"ASP4345","slug":"asp4345","indication":"Treatment of autoimmune hemolytic anemia","status":"phase_2"},{"name":"ASP9831","genericName":"ASP9831","slug":"asp9831","indication":"Treatment of autoimmune hemolytic anemia","status":"phase_2"},{"name":"ATF-Fresenius S","genericName":"ATF-Fresenius S","slug":"atf-fresenius-s","indication":"Rheumatoid Arthritis","status":"phase_2"},{"name":"Anti-IL2R AB","genericName":"Anti-IL2R AB","slug":"anti-il2r-ab","indication":"Rheumatoid Arthritis","status":"phase_2"},{"name":"CZP","genericName":"CZP","slug":"czp","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"FK506MR","genericName":"FK506MR","slug":"fk506mr","indication":"Organ transplant rejection prevention","status":"phase_3"},{"name":"Fluticasone 0.005%","genericName":"Fluticasone 0.005%","slug":"fluticasone-0-005","indication":"Inflammatory skin conditions (e.g., eczema, dermatitis, psoriasis)","status":"marketed"},{"name":"Tacrolimus (Prograf®)","genericName":"Tacrolimus (Prograf®)","slug":"tacrolimus-prograf","indication":"Prevention of organ rejection in kidney, heart, and liver transplant recipients","status":"marketed"},{"name":"Tacrolimus prolonged-release formulation","genericName":"Tacrolimus prolonged-release formulation","slug":"tacrolimus-prolonged-release-formulation","indication":"Prophylaxis of organ rejection in allogeneic kidney, heart, and liver transplant recipients","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":600000000,"percentOfTotal":6.2,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Evrenzo","genericName":"ROXADUSTAT","slug":"roxadustat","indication":"Anemia in chronic kidney disease","status":"marketed","revenue":600000000},{"name":"ASP0113","genericName":"ASP0113","slug":"asp0113","indication":"Prevention of cytomegalovirus (CMV) reactivation in CMV-seropositive recipients of hematopoietic stem cell transplantation","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":97,"colorKey":"neuroscience","drugs":[{"name":"Padcev Ejfv","genericName":"enfortumab-vedotin","slug":"enfortumab-vedotin","indication":"Other","status":"marketed"},{"name":"Tacrolimus immediate release","genericName":"Tacrolimus immediate release","slug":"tacrolimus-immediate-release","indication":"Other","status":"marketed"},{"name":"AGS15E","genericName":"AGS15E","slug":"ags15e","indication":"Other","status":"phase_1"},{"name":"ASP015K","genericName":"ASP015K","slug":"asp015k","indication":"Other","status":"phase_1"},{"name":"ASP0777","genericName":"ASP0777","slug":"asp0777","indication":"Other","status":"phase_1"},{"name":"ASP0892","genericName":"ASP0892","slug":"asp0892","indication":"Other","status":"phase_1"},{"name":"ASP1240","genericName":"ASP1240","slug":"asp1240","indication":"Other","status":"phase_1"},{"name":"ASP5094","genericName":"ASP5094","slug":"asp5094","indication":"Other","status":"phase_2"},{"name":"ASP5354","genericName":"ASP5354","slug":"asp5354","indication":"Other","status":"phase_1"},{"name":"ASP5834","genericName":"ASP5834","slug":"asp5834","indication":"Other","status":"phase_1"},{"name":"ASP7517","genericName":"ASP7517","slug":"asp7517","indication":"Other","status":"phase_1"},{"name":"ASP9801","genericName":"ASP9801","slug":"asp9801","indication":"Other","status":"phase_1"},{"name":"Adenocard","genericName":"ADENOSINE","slug":"adenosine","indication":"Myocardial Perfusion Imaging Adjunct","status":"marketed"},{"name":"Corticosteroid","genericName":"Corticosteroid","slug":"corticosteroid","indication":"Other","status":"marketed"},{"name":"FK463","genericName":"FK463","slug":"fk463","indication":"Invasive candidiasis","status":"phase_3"},{"name":"MR4","genericName":"MR4","slug":"mr4","indication":"Other","status":"phase_3"},{"name":"Mirabegron tablet","genericName":"Mirabegron tablet","slug":"mirabegron-tablet","indication":"Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency","status":"marketed"},{"name":"Simulect","genericName":"Simulect","slug":"simulect","indication":"Renal transplant rejection","status":"marketed"},{"name":"steroids","genericName":"steroids","slug":"steroids","indication":"Other","status":"marketed"},{"name":"14C-labeled gilteritinib","genericName":"14C-labeled gilteritinib","slug":"14c-labeled-gilteritinib","indication":"Other","status":"phase_1"},{"name":"AGS-16M8F","genericName":"AGS-16M8F","slug":"ags-16m8f","indication":"Other","status":"phase_1"},{"name":"AGS-1C4D4","genericName":"AGS-1C4D4","slug":"ags-1c4d4","indication":"Other","status":"phase_2"},{"name":"ASK8007","genericName":"ASK8007","slug":"ask8007","indication":"Other","status":"phase_1"},{"name":"ASP015K IR","genericName":"ASP015K IR","slug":"asp015k-ir","indication":"Other","status":"phase_1"},{"name":"ASP0892 Intradermal","genericName":"ASP0892 Intradermal","slug":"asp0892-intradermal","indication":"Other","status":"phase_1"},{"name":"ASP0892 Intramuscular","genericName":"ASP0892 Intramuscular","slug":"asp0892-intramuscular","indication":"Other","status":"phase_1"},{"name":"ASP1002","genericName":"ASP1002","slug":"asp1002","indication":"Other","status":"phase_1"},{"name":"ASP1128","genericName":"ASP1128","slug":"asp1128","indication":"Other","status":"phase_2"},{"name":"ASP1517","genericName":"ASP1517","slug":"asp1517","indication":"Treatment of gout","status":"phase_2"},{"name":"ASP1570","genericName":"ASP1570","slug":"asp1570","indication":"Other","status":"phase_1"},{"name":"ASP1617","genericName":"ASP1617","slug":"asp1617","indication":"Other","status":"phase_1"},{"name":"ASP1707 multiple dose of dose levels 1-2","genericName":"ASP1707 multiple dose of dose levels 1-2","slug":"asp1707-multiple-dose-of-dose-levels-1-2","indication":"Other","status":"phase_1"},{"name":"ASP1707 multiple dose of dose levels 1-4","genericName":"ASP1707 multiple dose of dose levels 1-4","slug":"asp1707-multiple-dose-of-dose-levels-1-4","indication":"Other","status":"phase_1"},{"name":"ASP1707 single dose fasted","genericName":"ASP1707 single dose fasted","slug":"asp1707-single-dose-fasted","indication":"Other","status":"phase_1"},{"name":"ASP1707 single dose fed","genericName":"ASP1707 single dose fed","slug":"asp1707-single-dose-fed","indication":"Other","status":"phase_1"},{"name":"ASP1707 single dose of dose levels 1 -7","genericName":"ASP1707 single dose of dose levels 1 -7","slug":"asp1707-single-dose-of-dose-levels-1-7","indication":"Other","status":"phase_1"},{"name":"ASP1948","genericName":"ASP1948","slug":"asp1948","indication":"Other","status":"phase_1"},{"name":"ASP2138","genericName":"ASP2138","slug":"asp2138","indication":"Other","status":"phase_1"},{"name":"ASP2246","genericName":"ASP2246","slug":"asp2246","indication":"Other","status":"phase_1"},{"name":"ASP2390","genericName":"ASP2390","slug":"asp2390","indication":"Other","status":"phase_1"},{"name":"ASP2408","genericName":"ASP2408","slug":"asp2408","indication":"Other","status":"phase_1"},{"name":"ASP2409","genericName":"ASP2409","slug":"asp2409","indication":"Other","status":"phase_1"},{"name":"ASP2998","genericName":"ASP2998","slug":"asp2998","indication":"Other","status":"phase_1"},{"name":"ASP3026","genericName":"ASP3026","slug":"asp3026","indication":"Other","status":"phase_1"},{"name":"ASP3325","genericName":"ASP3325","slug":"asp3325","indication":"Other","status":"phase_1"},{"name":"ASP3652","genericName":"ASP3652","slug":"asp3652","indication":"Complement-mediated inflammatory disorders (Phase 2 development)","status":"phase_2"},{"name":"ASP4058","genericName":"ASP4058","slug":"asp4058","indication":"Other","status":"phase_1"},{"name":"ASP4070","genericName":"ASP4070","slug":"asp4070","indication":"Complement-mediated inflammatory diseases (Phase 2 development)","status":"phase_2"},{"name":"ASP4132","genericName":"ASP4132","slug":"asp4132","indication":"Other","status":"phase_1"},{"name":"ASP4396","genericName":"ASP4396","slug":"asp4396","indication":"Other","status":"phase_1"},{"name":"ASP4901","genericName":"ASP4901","slug":"asp4901","indication":"Other","status":"phase_2"},{"name":"ASP546C","genericName":"ASP546C","slug":"asp546c","indication":"Other","status":"phase_1"},{"name":"ASP5502","genericName":"ASP5502","slug":"asp5502","indication":"Other","status":"phase_1"},{"name":"ASP5878","genericName":"ASP5878","slug":"asp5878","indication":"Other","status":"phase_1"},{"name":"ASP6282","genericName":"ASP6282","slug":"asp6282","indication":"Other","status":"phase_1"},{"name":"ASP6294 Intravenous","genericName":"ASP6294 Intravenous","slug":"asp6294-intravenous","indication":"Other","status":"phase_1"},{"name":"ASP6294 Subcutaneous","genericName":"ASP6294 Subcutaneous","slug":"asp6294-subcutaneous","indication":"Other","status":"phase_1"},{"name":"ASP6858","genericName":"ASP6858","slug":"asp6858","indication":"Other","status":"phase_1"},{"name":"ASP6981","genericName":"ASP6981","slug":"asp6981","indication":"Other","status":"phase_1"},{"name":"ASP7713","genericName":"ASP7713","slug":"asp7713","indication":"Other","status":"phase_1"},{"name":"ASP8082","genericName":"ASP8082","slug":"asp8082","indication":"Other","status":"phase_1"},{"name":"ASP8302","genericName":"ASP8302","slug":"asp8302","indication":"Other","status":"phase_2"},{"name":"AST-120 (Kremezin®)","genericName":"AST-120 (Kremezin®)","slug":"ast-120-kremezin","indication":"Chronic kidney disease (CKD) to reduce uremic toxins and slow disease progression","status":"marketed"},{"name":"ATG-F","genericName":"ATG-F","slug":"atg-f","indication":"Other","status":"marketed"},{"name":"Advagraf","genericName":"Advagraf","slug":"advagraf","indication":"Other","status":"marketed"},{"name":"Betanis","genericName":"Betanis","slug":"betanis","indication":"Other","status":"phase_2"},{"name":"Betmiga®","genericName":"Betmiga®","slug":"betmiga","indication":"Prevention of kidney stones","status":"phase_2"},{"name":"Bisphonal","genericName":"INCADRONIC ACID","slug":"incadronic-acid","indication":"Humoral hypercalcemia of malignancy","status":"marketed"},{"name":"ESN364","genericName":"ESN364","slug":"esn364","indication":"Other","status":"phase_1"},{"name":"FK199B","genericName":"FK199B","slug":"fk199b","indication":"Complement-mediated inflammatory disorders (specific indication under investigation in Phase 3)","status":"phase_3"},{"name":"FK949E","genericName":"FK949E","slug":"fk949e","indication":"Muscle wasting / sarcopenia","status":"phase_3"},{"name":"Imidafenacin tablet","genericName":"Imidafenacin tablet","slug":"imidafenacin-tablet","indication":"Other","status":"marketed"},{"name":"Izervay","genericName":"AVACINCAPTAD PEGOL","slug":"avacincaptad-pegol","indication":"Geographic atrophy (GA) secondary to AMD","status":"marketed"},{"name":"Minidril","genericName":"Minidril","slug":"minidril","indication":"Other","status":"phase_1"},{"name":"Mycophenolic acid drugs","genericName":"Mycophenolic acid drugs","slug":"mycophenolic-acid-drugs","indication":"Other","status":"marketed"},{"name":"Perdipine injection","genericName":"Perdipine injection","slug":"perdipine-injection","indication":"Other","status":"marketed"},{"name":"Placebo to Mirabegron","genericName":"Placebo to Mirabegron","slug":"placebo-to-mirabegron","indication":"Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency","status":"phase_3"},{"name":"Placebo to Tolterodine","genericName":"Placebo to Tolterodine","slug":"placebo-to-tolterodine","indication":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency","status":"phase_3"},{"name":"Placebo to match mirabegron","genericName":"Placebo to match mirabegron","slug":"placebo-to-match-mirabegron","indication":"Placebo control for mirabegron trials in overactive bladder","status":"phase_3"},{"name":"Placebo to match solifenacin succinate","genericName":"Placebo to match solifenacin succinate","slug":"placebo-to-match-solifenacin-succinate","indication":"Placebo control for solifenacin succinate trials in overactive bladder","status":"phase_3"},{"name":"Plaebo","genericName":"Plaebo","slug":"plaebo","indication":"Other","status":"phase_3"},{"name":"Prograf-XL","genericName":"Prograf-XL","slug":"prograf-xl","indication":"Prevention of organ rejection in kidney transplant patients","status":"phase_3"},{"name":"Regnite","genericName":"Regnite","slug":"regnite","indication":"Other","status":"phase_2"},{"name":"Tamsulosin OCAS","genericName":"Tamsulosin OCAS","slug":"tamsulosin-ocas","indication":"Other","status":"marketed"},{"name":"Tamuslosin","genericName":"Tamuslosin","slug":"tamuslosin","indication":"Other","status":"phase_3"},{"name":"Tamusulosin","genericName":"Tamusulosin","slug":"tamusulosin","indication":"Other","status":"phase_3"},{"name":"VYLOY","genericName":"ZOLBETUXIMAB-CLZB","slug":"zolbetuximab-clzb","indication":"Other","status":"marketed"},{"name":"Vesicare","genericName":"SOLIFENACIN","slug":"solifenacin","indication":"Bladder muscle dysfunction - overactive","status":"marketed"},{"name":"Zolpidem (Myslee®)","genericName":"Zolpidem (Myslee®)","slug":"zolpidem-myslee","indication":"Insomnia (sleep onset and maintenance)","status":"marketed"},{"name":"Zolpidem IR","genericName":"Zolpidem IR","slug":"zolpidem-ir","indication":"Insomnia (sleep-onset difficulties)","status":"marketed"},{"name":"Zolpidem MR","genericName":"Zolpidem MR","slug":"zolpidem-mr","indication":"Insomnia (sleep onset and sleep maintenance)","status":"marketed"},{"name":"atrovastatin","genericName":"atrovastatin","slug":"atrovastatin","indication":"Other","status":"phase_2"},{"name":"bismuth tripotassium dicitrate","genericName":"bismuth tripotassium dicitrate","slug":"bismuth-tripotassium-dicitrate","indication":"Other","status":"marketed"},{"name":"cyclosporine microemulsion","genericName":"cyclosporine microemulsion","slug":"cyclosporine-microemulsion","indication":"Other","status":"marketed"},{"name":"isavuconazonium sulfate - oral","genericName":"isavuconazonium sulfate - oral","slug":"isavuconazonium-sulfate-oral","indication":"Other","status":"phase_1"},{"name":"oxybutynin immediate release","genericName":"oxybutynin immediate release","slug":"oxybutynin-immediate-release","indication":"Other","status":"marketed"},{"name":"solifenacin succinate suspension","genericName":"solifenacin succinate suspension","slug":"solifenacin-succinate-suspension","indication":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"rare","drugs":[{"name":"Cresemba","genericName":"ISAVUCONAZONIUM","slug":"isavuconazonium","indication":"Invasive Aspergillosis","status":"marketed"},{"name":"OPT-80","genericName":"OPT-80","slug":"opt-80","indication":"Clostridioides difficile infection (CDI)","status":"phase_3"},{"name":"Vancomycin capsules","genericName":"Vancomycin capsules","slug":"vancomycin-capsules","indication":"Treatment of infections caused by susceptible Gram-positive bacteria, including MRSA","status":"phase_3"},{"name":"Vancomycin oral liquid","genericName":"Vancomycin oral liquid","slug":"vancomycin-oral-liquid","indication":"Treatment of Clostridioides difficile infection","status":"phase_3"},{"name":"AC VAX","genericName":"AC VAX","slug":"ac-vax","indication":"COVID-19 prevention","status":"phase_2"},{"name":"Abelcet","genericName":"AMPHOTERICIN B","slug":"amphotericin-b","indication":"Acne vulgaris","status":"marketed"},{"name":"Fidaxomicin oral suspension","genericName":"Fidaxomicin oral suspension","slug":"fidaxomicin-oral-suspension","indication":"Clostridioides difficile infection (CDI), including initial and recurrent episodes","status":"phase_3"},{"name":"Fidaxomicin tablets","genericName":"Fidaxomicin tablets","slug":"fidaxomicin-tablets","indication":"Clostridioides difficile infection (CDI), including initial episode and recurrent infection","status":"phase_3"},{"name":"Micafungin (Mycamine)","genericName":"Micafungin (Mycamine)","slug":"micafungin-mycamine","indication":"Candidemia and acute disseminated candidiasis","status":"phase_3"},{"name":"polyvalent pneumococcal vaccine","genericName":"polyvalent pneumococcal vaccine","slug":"polyvalent-pneumococcal-vaccine","indication":"Prevention of invasive pneumococcal disease caused by susceptible serotypes of Streptococcus pneumoniae","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"infectious","drugs":[{"name":"ASP0819","genericName":"ASP0819","slug":"asp0819","indication":"Treatment of relapsing forms of multiple sclerosis","status":"phase_2"},{"name":"Veozah","genericName":"FEZOLINETANT","slug":"fezolinetant","indication":"Vasomotor symptoms due to menopause","status":"marketed"},{"name":"YM443","genericName":"YM443","slug":"ym443","indication":"Major depressive disorder","status":"phase_3"},{"name":"ASP6294","genericName":"ASP6294","slug":"asp6294","indication":"Relapsing multiple sclerosis","status":"phase_2"},{"name":"ASP7962","genericName":"ASP7962","slug":"asp7962","indication":"Relapsing multiple sclerosis","status":"phase_2"},{"name":"overencapsulated caffeine","genericName":"overencapsulated caffeine","slug":"overencapsulated-caffeine","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"respiratory","drugs":[{"name":"ASP3550","genericName":"ASP3550","slug":"asp3550","indication":"Treatment of type 2 diabetes","status":"phase_2"},{"name":"YM177","genericName":"YM177","slug":"ym177","indication":"Type 2 diabetes","status":"phase_3"},{"name":"YM150","genericName":"YM150","slug":"ym150","indication":"Type 2 diabetes","status":"phase_3"},{"name":"YM178","genericName":"YM178","slug":"ym178","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"ophthalmology","drugs":[{"name":"Locobase® REPAIR","genericName":"Locobase® REPAIR","slug":"locobase-repair","indication":"Dry skin and skin barrier dysfunction","status":"marketed"},{"name":"Tacrolimus Ointment 0.03%","genericName":"Tacrolimus Ointment 0.03%","slug":"tacrolimus-ointment-0-03","indication":"Atopic dermatitis (eczema)","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"YM060","genericName":"YM060","slug":"ym060","indication":"Chronic pain","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"dermatology","drugs":[{"name":"RSD1235","genericName":"RSD1235","slug":"rsd1235","indication":"Atrial fibrillation (acute conversion and prevention of recurrence)","status":"phase_3"}]}],"pipeline":[{"name":"Xtandi","genericName":"enzalutamide","slug":"enzalutamide","phase":"marketed","mechanism":"Xtandi works by blocking the androgen receptor, a protein that helps prostate cancer cells grow.","indications":["Malignant tumor of prostate","Metastasis from malignant tumor of prostate"],"catalyst":""},{"name":"Padcev","genericName":"AGS-22M6E","slug":"ags-22m6e","phase":"marketed","mechanism":"Padcev works by binding to Nectin-4 on the surface of cancer cells, marking them for destruction.","indications":["Metastatic urothelial carcinoma"],"catalyst":""},{"name":"Prograf","genericName":"TACROLIMUS","slug":"tacrolimus","phase":"marketed","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell.","indications":["Atopic dermatitis","Intractable Eczema","Liver transplant rejection","Prevention of Cardiac Transplant Rejection","Prevention of Kidney Transplant Rejection"],"catalyst":""},{"name":"Xospata","genericName":"GILTERITINIB","slug":"gilteritinib","phase":"marketed","mechanism":"Xospata works by blocking the activity of a specific enzyme called Leukocyte tyrosine kinase receptor.","indications":["Acute myeloid leukemia, disease"],"catalyst":""},{"name":"Evrenzo","genericName":"ROXADUSTAT","slug":"roxadustat","phase":"marketed","mechanism":"Thyroid hormone receptor beta","indications":["Anemia in chronic kidney disease","Refractory anemia (clinical)"],"catalyst":""},{"name":"Vyloy","genericName":"ZOLBETUXIMAB","slug":"zolbetuximab","phase":"marketed","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction.","indications":["locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma","locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma"],"catalyst":""},{"name":"Xtandi","genericName":"xtandi","slug":"xtandi","phase":"marketed","mechanism":"Enzalutamide competitively inhibits androgen binding to androgen receptors, blocking nuclear translocation and DNA interaction.","indications":["Malignant tumor of prostate","Metastasis from malignant tumor of prostate"],"catalyst":""},{"name":"Enfortumab","genericName":"padcev","slug":"padcev","phase":"marketed","mechanism":"Nectin-4","indications":["Metastatic urothelial carcinoma"],"catalyst":""},{"name":"Padcev Ejfv","genericName":"enfortumab-vedotin","slug":"enfortumab-vedotin","phase":"marketed","mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4, internalizes, releases MMAE, disrupting microtubules and causing cell death.","indications":[],"catalyst":""},{"name":"Tacrolimus immediate release","genericName":"Tacrolimus immediate release","slug":"tacrolimus-immediate-release","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGS15E","genericName":"AGS15E","slug":"ags15e","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP015K","genericName":"ASP015K","slug":"asp015k","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP0777","genericName":"ASP0777","slug":"asp0777","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP0819","genericName":"ASP0819","slug":"asp0819","phase":"phase_2","mechanism":"ASP0819 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Treatment of relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"ASP0892","genericName":"ASP0892","slug":"asp0892","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1240","genericName":"ASP1240","slug":"asp1240","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP3550","genericName":"ASP3550","slug":"asp3550","phase":"phase_2","mechanism":"ASP3550 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"ASP5094","genericName":"ASP5094","slug":"asp5094","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP5354","genericName":"ASP5354","slug":"asp5354","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP5541","genericName":"ASP5541","slug":"asp5541","phase":"phase_2","mechanism":"ASP5541 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","indications":["Inflammatory and autoimmune disorders (specific indications under investigation in phase 2)"],"catalyst":""},{"name":"ASP5834","genericName":"ASP5834","slug":"asp5834","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP7517","genericName":"ASP7517","slug":"asp7517","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ASP8232","genericName":"ASP8232","slug":"asp8232","phase":"phase_2","mechanism":"ASP8232 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Treatment of autoimmune diseases"],"catalyst":""},{"name":"ASP8477","genericName":"ASP8477","slug":"asp8477","phase":"phase_2","mechanism":"ASP8477 is a small molecule that targets the CDK9 protein.","indications":["Relapsed or refractory non-Hodgkin lymphoma"],"catalyst":""},{"name":"ASP9801","genericName":"ASP9801","slug":"asp9801","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Adenocard","genericName":"ADENOSINE","slug":"adenosine","phase":"marketed","mechanism":"Adenosine receptor A3","indications":["Myocardial Perfusion Imaging Adjunct","Paroxysmal supraventricular tachycardia"],"catalyst":""},{"name":"Amevive","genericName":"ALEFACEPT","slug":"alefacept","phase":"marketed","mechanism":"T-cell surface antigen CD2","indications":["Plaque psoriasis"],"catalyst":""},{"name":"Corticosteroid","genericName":"Corticosteroid","slug":"corticosteroid","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cresemba","genericName":"ISAVUCONAZONIUM","slug":"isavuconazonium","phase":"marketed","mechanism":"Isavuconazonium sulfate is a prodrug that converts to isavuconazole, an azole antifungal.","indications":["Invasive Aspergillosis","Invasive Mucormycosis"],"catalyst":""},{"name":"FK463","genericName":"FK463","slug":"fk463","phase":"phase_3","mechanism":"FK463 is a fungal cell wall synthesis inhibitor that disrupts β-glucan formation, leading to fungal cell death.","indications":["Invasive candidiasis","Invasive aspergillosis"],"catalyst":""},{"name":"FK506E","genericName":"FK506E","slug":"fk506e","phase":"phase_3","mechanism":"FK506E is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, preventing IL-2 production and T-cell proliferation.","indications":["Prevention of organ rejection in transplant recipients","Autoimmune and inflammatory conditions (phase 3 development)"],"catalyst":""},{"name":"MR4","genericName":"MR4","slug":"mr4","phase":"phase_3","mechanism":"MR4 is an investigational compound in development by Astellas Pharma, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"Mirabegron tablet","genericName":"Mirabegron tablet","slug":"mirabegron-tablet","phase":"marketed","mechanism":"Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity.","indications":["Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency"],"catalyst":""},{"name":"OPT-80","genericName":"OPT-80","slug":"opt-80","phase":"phase_3","mechanism":"OPT-80 is a macrocyclic antibiotic that inhibits bacterial protein synthesis by binding to the bacterial ribosome.","indications":["Clostridioides difficile infection (CDI)"],"catalyst":""},{"name":"Simulect","genericName":"Simulect","slug":"simulect","phase":"marketed","mechanism":"Interleukin-2 receptor subunit alpha","indications":["Renal transplant rejection"],"catalyst":""},{"name":"Tacrolimus immediate-release formulation","genericName":"Tacrolimus immediate-release formulation","slug":"tacrolimus-immediate-release-formulation","phase":"marketed","mechanism":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation to suppress immune responses.","indications":["Organ transplant rejection prophylaxis (kidney, heart, liver)","Atopic dermatitis","Autoimmune conditions (off-label use in various settings)"],"catalyst":""},{"name":"Tacrolimus sustained-release capsule","genericName":"Tacrolimus sustained-release capsule","slug":"tacrolimus-sustained-release-capsule","phase":"marketed","mechanism":"Tacrolimus inhibits calcineurin phosphatase, suppressing T-cell activation and proliferation to prevent organ rejection and treat autoimmune conditions.","indications":["Prophylaxis of organ rejection in allogeneic kidney, heart, and liver transplant recipients","Atopic dermatitis (eczema)","Autoimmune conditions requiring immunosuppression"],"catalyst":""},{"name":"Vancomycin capsules","genericName":"Vancomycin capsules","slug":"vancomycin-capsules","phase":"phase_3","mechanism":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.","indications":["Treatment of infections caused by susceptible Gram-positive bacteria, including MRSA"],"catalyst":""},{"name":"Vancomycin oral liquid","genericName":"Vancomycin oral liquid","slug":"vancomycin-oral-liquid","phase":"phase_3","mechanism":"Vancomycin oral liquid inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursors.","indications":["Treatment of Clostridioides difficile infection","Treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections"],"catalyst":""},{"name":"Veozah","genericName":"FEZOLINETANT","slug":"fezolinetant","phase":"marketed","mechanism":"Veozah works by binding to the Neuromedin-K receptor, which helps to alleviate vasomotor symptoms.","indications":["Vasomotor symptoms due to menopause"],"catalyst":""},{"name":"YM060","genericName":"YM060","slug":"ym060","phase":"phase_3","mechanism":"YM060 is a selective and potent kappa opioid receptor antagonist.","indications":["Chronic pain"],"catalyst":""},{"name":"YM177","genericName":"YM177","slug":"ym177","phase":"phase_3","mechanism":"YM177 is a glucagon-like peptide-1 (GLP-1) receptor agonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"YM443","genericName":"YM443","slug":"ym443","phase":"phase_3","mechanism":"YM443 is a selective and potent inhibitor of the serotonin reuptake transporter.","indications":["Major depressive disorder"],"catalyst":""},{"name":"steroids","genericName":"steroids","slug":"steroids","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-labeled gilteritinib","genericName":"14C-labeled gilteritinib","slug":"14c-labeled-gilteritinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AC VAX","genericName":"AC VAX","slug":"ac-vax","phase":"phase_2","mechanism":"AC VAX is a vaccine that stimulates the body's immune system to produce antibodies against a specific antigen.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"AGS-16M8F","genericName":"AGS-16M8F","slug":"ags-16m8f","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGS-1C4D4","genericName":"AGS-1C4D4","slug":"ags-1c4d4","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASK8007","genericName":"ASK8007","slug":"ask8007","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASKP1240","genericName":"ASKP1240","slug":"askp1240","phase":"phase_2","mechanism":"ASKP1240 is a small molecule inhibitor of the PI3Kδ enzyme.","indications":["Relapsed or refractory follicular lymphoma","Relapsed or refractory marginal zone lymphoma"],"catalyst":""},{"name":"ASP0113","genericName":"ASP0113","slug":"asp0113","phase":"phase_3","mechanism":"ASP0113 is a therapeutic vaccine that stimulates the immune system to recognize and eliminate cells infected with cytomegalovirus (CMV).","indications":["Prevention of cytomegalovirus (CMV) reactivation in CMV-seropositive recipients of hematopoietic stem cell transplantation","Prevention of CMV reactivation in solid organ transplant recipients"],"catalyst":""},{"name":"ASP015K IR","genericName":"ASP015K IR","slug":"asp015k-ir","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP0456","genericName":"ASP0456","slug":"asp0456","phase":"phase_2","mechanism":"ASP0456 is a small molecule inhibitor of the CDK9 enzyme.","indications":["Relapsed or refractory diffuse large B-cell lymphoma","Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"ASP0892 Intradermal","genericName":"ASP0892 Intradermal","slug":"asp0892-intradermal","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP0892 Intramuscular","genericName":"ASP0892 Intramuscular","slug":"asp0892-intramuscular","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1002","genericName":"ASP1002","slug":"asp1002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1128","genericName":"ASP1128","slug":"asp1128","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1517","genericName":"ASP1517","slug":"asp1517","phase":"phase_2","mechanism":"ASP1517 is a selective and potent inhibitor of the NLRP3 inflammasome.","indications":["Treatment of gout"],"catalyst":""},{"name":"ASP1570","genericName":"ASP1570","slug":"asp1570","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1585","genericName":"ASP1585","slug":"asp1585","phase":"phase_3","mechanism":"ASP1585 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","indications":["Castration-resistant prostate cancer (CRPC)","Hormone-sensitive prostate cancer"],"catalyst":""},{"name":"ASP1617","genericName":"ASP1617","slug":"asp1617","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1650","genericName":"ASP1650","slug":"asp1650","phase":"phase_2","mechanism":"ASP1650 is a selective antagonist of the prostaglandin E receptor EP4, which reduces inflammatory signaling and immune suppression in the tumor microenvironment.","indications":["Advanced solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"ASP1707","genericName":"ASP1707","slug":"asp1707","phase":"phase_2","mechanism":"ASP1707 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Treatment of autoimmune diseases"],"catalyst":""},{"name":"ASP1707 multiple dose of dose levels 1-2","genericName":"ASP1707 multiple dose of dose levels 1-2","slug":"asp1707-multiple-dose-of-dose-levels-1-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 multiple dose of dose levels 1-4","genericName":"ASP1707 multiple dose of dose levels 1-4","slug":"asp1707-multiple-dose-of-dose-levels-1-4","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 single dose fasted","genericName":"ASP1707 single dose fasted","slug":"asp1707-single-dose-fasted","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 single dose fed","genericName":"ASP1707 single dose fed","slug":"asp1707-single-dose-fed","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 single dose of dose levels 1 -7","genericName":"ASP1707 single dose of dose levels 1 -7","slug":"asp1707-single-dose-of-dose-levels-1-7","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1948","genericName":"ASP1948","slug":"asp1948","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP2138","genericName":"ASP2138","slug":"asp2138","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP2215","genericName":"ASP2215","slug":"asp2215","phase":"phase_2","mechanism":"ASP2215 is a selective and potent inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.","indications":["Non-small cell lung cancer with ALK rearrangement","Ceritinib-resistant non-small cell lung cancer with ALK rearrangement"],"catalyst":""},{"name":"ASP2246","genericName":"ASP2246","slug":"asp2246","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP2390","genericName":"ASP2390","slug":"asp2390","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ASP2408","genericName":"ASP2408","slug":"asp2408","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP2409","genericName":"ASP2409","slug":"asp2409","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP2998","genericName":"ASP2998","slug":"asp2998","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP3026","genericName":"ASP3026","slug":"asp3026","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP3325","genericName":"ASP3325","slug":"asp3325","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP3652","genericName":"ASP3652","slug":"asp3652","phase":"phase_2","mechanism":"ASP3652 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","indications":["Complement-mediated inflammatory disorders (Phase 2 development)"],"catalyst":""},{"name":"ASP4058","genericName":"ASP4058","slug":"asp4058","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP4070","genericName":"ASP4070","slug":"asp4070","phase":"phase_2","mechanism":"ASP4070 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","indications":["Complement-mediated inflammatory diseases (Phase 2 development)"],"catalyst":""},{"name":"ASP4132","genericName":"ASP4132","slug":"asp4132","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP4345","genericName":"ASP4345","slug":"asp4345","phase":"phase_2","mechanism":"ASP4345 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Treatment of autoimmune hemolytic anemia"],"catalyst":""},{"name":"ASP4396","genericName":"ASP4396","slug":"asp4396","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP4901","genericName":"ASP4901","slug":"asp4901","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP546C","genericName":"ASP546C","slug":"asp546c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP5502","genericName":"ASP5502","slug":"asp5502","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP5878","genericName":"ASP5878","slug":"asp5878","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6282","genericName":"ASP6282","slug":"asp6282","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6294","genericName":"ASP6294","slug":"asp6294","phase":"phase_2","mechanism":"ASP6294 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"ASP6294 Intravenous","genericName":"ASP6294 Intravenous","slug":"asp6294-intravenous","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6294 Subcutaneous","genericName":"ASP6294 Subcutaneous","slug":"asp6294-subcutaneous","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6858","genericName":"ASP6858","slug":"asp6858","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6981","genericName":"ASP6981","slug":"asp6981","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP7713","genericName":"ASP7713","slug":"asp7713","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP7962","genericName":"ASP7962","slug":"asp7962","phase":"phase_2","mechanism":"ASP7962 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"ASP8082","genericName":"ASP8082","slug":"asp8082","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP8302","genericName":"ASP8302","slug":"asp8302","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP9831","genericName":"ASP9831","slug":"asp9831","phase":"phase_2","mechanism":"ASP9831 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Treatment of autoimmune hemolytic anemia"],"catalyst":""},{"name":"AST-120 (Kremezin®)","genericName":"AST-120 (Kremezin®)","slug":"ast-120-kremezin","phase":"marketed","mechanism":"AST-120 is an oral adsorbent that binds uremic toxins and other waste products in the gastrointestinal tract to reduce their systemic absorption and accumulation.","indications":["Chronic kidney disease (CKD) to reduce uremic toxins and slow disease progression","End-stage renal disease (ESRD) in dialysis patients"],"catalyst":""},{"name":"ATF-Fresenius S","genericName":"ATF-Fresenius S","slug":"atf-fresenius-s","phase":"phase_2","mechanism":"ATF-Fresenius S is a drug that works by modulating the immune system.","indications":["Rheumatoid Arthritis"],"catalyst":""},{"name":"ATG-F","genericName":"ATG-F","slug":"atg-f","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Abelcet","genericName":"AMPHOTERICIN B","slug":"amphotericin-b","phase":"marketed","mechanism":"Small molecule","indications":["Acne vulgaris","Actinomycotic infection","Acute gonococcal cervicitis","Acute gonococcal urethritis","Anthrax"],"catalyst":""},{"name":"Advagraf","genericName":"Advagraf","slug":"advagraf","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anti-IL2R AB","genericName":"Anti-IL2R AB","slug":"anti-il2r-ab","phase":"phase_2","mechanism":"Anti-IL2R antibody","indications":["Rheumatoid Arthritis","Psoriasis"],"catalyst":""},{"name":"Betanis","genericName":"Betanis","slug":"betanis","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Betmiga®","genericName":"Betmiga®","slug":"betmiga","phase":"phase_2","mechanism":"Betmiba works by increasing the levels of magnesium in the urine, which helps to prevent kidney stones.","indications":["Prevention of kidney stones"],"catalyst":""},{"name":"Bisphonal","genericName":"INCADRONIC ACID","slug":"incadronic-acid","phase":"marketed","mechanism":"Farnesyl pyrophosphate synthase","indications":["Humoral hypercalcemia of malignancy","Osteoporosis"],"catalyst":""},{"name":"CZP","genericName":"CZP","slug":"czp","phase":"phase_3","mechanism":"CZP is a humanized monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""},{"name":"Corticosteroids (Prednisone)","genericName":"Corticosteroids (Prednisone)","slug":"corticosteroids-prednisone","phase":"marketed","mechanism":"Prednisone is a corticosteroid that binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and suppresses inflammatory gene expression and immune cell activation.","indications":["Rheumatoid arthritis and other autoimmune inflammatory conditions","Adrenocortical insufficiency (Addison's disease)","Allergic reactions and asthma","Inflammatory bowel disease (Crohn's disease, ulcerative colitis)","Lymphomas and leukemias (as part of combination chemotherapy)"],"catalyst":""},{"name":"Cyclocort","genericName":"AMCINONIDE","slug":"amcinonide","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Atopic dermatitis","Contact dermatitis","Discoid lupus erythematosus","Eruption of skin","Granuloma annulare"],"catalyst":""},{"name":"Cyclophosphamide injections","genericName":"Cyclophosphamide injections","slug":"cyclophosphamide-injections","phase":"phase_3","mechanism":"Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells.","indications":["Lymphomas (Hodgkin and non-Hodgkin)","Breast cancer","Ovarian cancer","Leukemias","Multiple myeloma"],"catalyst":""},{"name":"ESN364","genericName":"ESN364","slug":"esn364","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eligard","genericName":"Eligard","slug":"eligard","phase":"marketed","mechanism":"Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor","indications":["Advanced Prostatic Carcinoma","Anemia due to Bleeding Uterine Leiomyoma","Endometriosis","Precocious puberty"],"catalyst":""},{"name":"FK199B","genericName":"FK199B","slug":"fk199b","phase":"phase_3","mechanism":"FK199B is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","indications":["Complement-mediated inflammatory disorders (specific indication under investigation in Phase 3)"],"catalyst":""},{"name":"FK506MR","genericName":"FK506MR","slug":"fk506mr","phase":"phase_3","mechanism":"FK506MR is a modified-release formulation of tacrolimus that suppresses T-cell activation by inhibiting calcineurin phosphatase.","indications":["Organ transplant rejection prevention","Autoimmune and inflammatory conditions"],"catalyst":""},{"name":"FK949E","genericName":"FK949E","slug":"fk949e","phase":"phase_3","mechanism":"FK949E is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.","indications":["Muscle wasting / sarcopenia","Osteoporosis"],"catalyst":""},{"name":"Fidaxomicin oral suspension","genericName":"Fidaxomicin oral suspension","slug":"fidaxomicin-oral-suspension","phase":"phase_3","mechanism":"Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora.","indications":["Clostridioides difficile infection (CDI), including initial and recurrent episodes"],"catalyst":""},{"name":"Fidaxomicin tablets","genericName":"Fidaxomicin tablets","slug":"fidaxomicin-tablets","phase":"phase_3","mechanism":"Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora.","indications":["Clostridioides difficile infection (CDI), including initial episode and recurrent infection"],"catalyst":""},{"name":"Fluticasone 0.005%","genericName":"Fluticasone 0.005%","slug":"fluticasone-0-005","phase":"marketed","mechanism":"Fluticasone is a corticosteroid that suppresses local immune and inflammatory responses by binding to glucocorticoid receptors.","indications":["Inflammatory skin conditions (e.g., eczema, dermatitis, psoriasis)","Pruritus and other dermatological inflammatory disorders"],"catalyst":""},{"name":"Graceptor®","genericName":"Graceptor®","slug":"graceptor","phase":"phase_2","mechanism":"Selective estrogen receptor modulator","indications":["Treatment of breast cancer"],"catalyst":""},{"name":"Imidafenacin tablet","genericName":"Imidafenacin tablet","slug":"imidafenacin-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Izervay","genericName":"AVACINCAPTAD PEGOL","slug":"avacincaptad-pegol","phase":"marketed","mechanism":"Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response.","indications":["Geographic atrophy (GA) secondary to AMD"],"catalyst":""},{"name":"LoDAC (Low Dose Cytarabine)","genericName":"LoDAC (Low Dose Cytarabine)","slug":"lodac-low-dose-cytarabine","phase":"phase_3","mechanism":"Low-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and blocking cell division, primarily affecting rapidly dividing hematopoietic cells.","indications":["Myelodysplastic syndrome (MDS)","Acute myeloid leukemia (AML) in elderly patients unfit for intensive chemotherapy"],"catalyst":""},{"name":"Locobase® REPAIR","genericName":"Locobase® REPAIR","slug":"locobase-repair","phase":"marketed","mechanism":"Locobase® REPAIR is an emollient and skin barrier repair product that restores skin hydration and protects damaged skin through occlusive and humectant ingredients.","indications":["Dry skin and skin barrier dysfunction","Symptomatic relief of xerosis and atopic dermatitis-prone skin"],"catalyst":""},{"name":"Micafungin (Mycamine)","genericName":"Micafungin (Mycamine)","slug":"micafungin-mycamine","phase":"phase_3","mechanism":"Micafungin inhibits fungal cell wall synthesis by targeting 1,3-beta-D-glucan synthase, leading to fungal cell death.","indications":["Candidemia and acute disseminated candidiasis","Esophageal candidiasis","Prophylaxis of Candida infections in hematopoietic stem cell transplant recipients"],"catalyst":""},{"name":"Minidril","genericName":"Minidril","slug":"minidril","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mycophenolic acid drugs","genericName":"Mycophenolic acid drugs","slug":"mycophenolic-acid-drugs","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Perdipine injection","genericName":"Perdipine injection","slug":"perdipine-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo to Mirabegron","genericName":"Placebo to Mirabegron","slug":"placebo-to-mirabegron","phase":"phase_3","mechanism":"Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity.","indications":["Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency"],"catalyst":""},{"name":"Placebo to Tolterodine","genericName":"Placebo to Tolterodine","slug":"placebo-to-tolterodine","phase":"phase_3","mechanism":"Tolterodine is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms.","indications":["Overactive bladder with symptoms of urge incontinence, urgency, and frequency"],"catalyst":""},{"name":"Placebo to match mirabegron","genericName":"Placebo to match mirabegron","slug":"placebo-to-match-mirabegron","phase":"phase_3","mechanism":"This is an inert placebo formulation designed to match the physical and sensory characteristics of mirabegron for blinded clinical trial purposes.","indications":["Placebo control for mirabegron trials in overactive bladder"],"catalyst":""},{"name":"Placebo to match solifenacin succinate","genericName":"Placebo to match solifenacin succinate","slug":"placebo-to-match-solifenacin-succinate","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration of solifenacin succinate for blinded clinical trial purposes.","indications":["Placebo control for solifenacin succinate trials in overactive bladder"],"catalyst":""},{"name":"Plaebo","genericName":"Plaebo","slug":"plaebo","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Prograf-XL","genericName":"Prograf-XL","slug":"prograf-xl","phase":"phase_3","mechanism":"Prograf-XL is an immunosuppressant that inhibits calcineurin.","indications":["Prevention of organ rejection in kidney transplant patients"],"catalyst":""},{"name":"RSD1235","genericName":"RSD1235","slug":"rsd1235","phase":"phase_3","mechanism":"RSD1235 is a potassium channel opener that suppresses atrial fibrillation by prolonging atrial refractoriness and reducing atrial conduction velocity.","indications":["Atrial fibrillation (acute conversion and prevention of recurrence)"],"catalyst":""},{"name":"Regnite","genericName":"Regnite","slug":"regnite","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tacrolimus (Prograf®)","genericName":"Tacrolimus (Prograf®)","slug":"tacrolimus-prograf","phase":"marketed","mechanism":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation to suppress immune responses.","indications":["Prevention of organ rejection in kidney, heart, and liver transplant recipients","Atopic dermatitis (topical formulation)","Severe refractory uveitis","Autoimmune conditions (off-label use)"],"catalyst":""},{"name":"Tacrolimus Ointment 0.03%","genericName":"Tacrolimus Ointment 0.03%","slug":"tacrolimus-ointment-0-03","phase":"marketed","mechanism":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce skin inflammation.","indications":["Atopic dermatitis (eczema)","Vitiligo"],"catalyst":""},{"name":"Tacrolimus prolonged-release formulation","genericName":"Tacrolimus prolonged-release formulation","slug":"tacrolimus-prolonged-release-formulation","phase":"marketed","mechanism":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby preventing immune rejection.","indications":["Prophylaxis of organ rejection in allogeneic kidney, heart, and liver transplant recipients","Autoimmune diseases including atopic dermatitis and other inflammatory conditions"],"catalyst":""},{"name":"Tamsulosin OCAS","genericName":"Tamsulosin OCAS","slug":"tamsulosin-ocas","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tamuslosin","genericName":"Tamuslosin","slug":"tamuslosin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tamusulosin","genericName":"Tamusulosin","slug":"tamusulosin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VYLOY","genericName":"ZOLBETUXIMAB-CLZB","slug":"zolbetuximab-clzb","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Vesicare","genericName":"SOLIFENACIN","slug":"solifenacin","phase":"marketed","mechanism":"Vesicare works by blocking the action of a chemical called acetylcholine at the muscarinic receptors in the bladder muscle, reducing muscle contractions and urgency.","indications":["Bladder muscle dysfunction - overactive","Increased Urinary Frequency","Urge incontinence of urine","Urgent desire to urinate"],"catalyst":""},{"name":"YM150","genericName":"YM150","slug":"ym150","phase":"phase_3","mechanism":"YM150 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"YM178","genericName":"YM178","slug":"ym178","phase":"phase_3","mechanism":"YM178 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Zolpidem (Myslee®)","genericName":"Zolpidem (Myslee®)","slug":"zolpidem-myslee","phase":"marketed","mechanism":"Zolpidem is a selective benzodiazepine receptor agonist that enhances inhibitory GABA signaling in the central nervous system to promote sleep onset.","indications":["Insomnia (sleep onset and maintenance)"],"catalyst":""},{"name":"Zolpidem IR","genericName":"Zolpidem IR","slug":"zolpidem-ir","phase":"marketed","mechanism":"Zolpidem binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep onset.","indications":["Insomnia (sleep-onset difficulties)","Short-term treatment of insomnia in adults"],"catalyst":""},{"name":"Zolpidem MR","genericName":"Zolpidem MR","slug":"zolpidem-mr","phase":"marketed","mechanism":"Zolpidem MR is a sedative-hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.","indications":["Insomnia (sleep onset and sleep maintenance)"],"catalyst":""},{"name":"atrovastatin","genericName":"atrovastatin","slug":"atrovastatin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bismuth tripotassium dicitrate","genericName":"bismuth tripotassium dicitrate","slug":"bismuth-tripotassium-dicitrate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"cyclosporine microemulsion","genericName":"cyclosporine microemulsion","slug":"cyclosporine-microemulsion","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"enfortumab vedotin (EV)","genericName":"enfortumab vedotin (EV)","slug":"enfortumab-vedotin-ev","phase":"phase_3","mechanism":"Enfortumab vedotin is a monoclonal antibody-drug conjugate that targets Nectin-4, a protein highly expressed on the surface of certain cancer cells.","indications":["Locally advanced or metastatic urothelial cancer","Locally advanced or metastatic non-small cell lung cancer"],"catalyst":""},{"name":"isavuconazonium sulfate - oral","genericName":"isavuconazonium sulfate - oral","slug":"isavuconazonium-sulfate-oral","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"methylprednisolone and prednisone","genericName":"methylprednisolone and prednisone","slug":"methylprednisolone-and-prednisone","phase":"phase_3","mechanism":"Methylprednisolone and prednisone are corticosteroids that suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis)","Allergic reactions and asthma exacerbations","Organ transplant rejection prophylaxis","Hematologic malignancies and lymphomas (as adjunctive therapy)"],"catalyst":""},{"name":"overencapsulated caffeine","genericName":"overencapsulated caffeine","slug":"overencapsulated-caffeine","phase":"phase_3","mechanism":"Overencapsulated caffeine acts as a stimulant by increasing the levels of dopamine and norepinephrine in the brain.","indications":["Attention deficit hyperactivity disorder (ADHD)","Narcolepsy"],"catalyst":""},{"name":"oxybutynin immediate release","genericName":"oxybutynin immediate release","slug":"oxybutynin-immediate-release","phase":"marketed","mechanism":"Oxybutynin is an anticholinergic that blocks muscarinic receptors in the bladder, leading to relaxation of the detrusor muscle and increased bladder capacity.","indications":[],"catalyst":""},{"name":"polyvalent pneumococcal vaccine","genericName":"polyvalent pneumococcal vaccine","slug":"polyvalent-pneumococcal-vaccine","phase":"marketed","mechanism":"A polyvalent pneumococcal vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae bacteria.","indications":["Prevention of invasive pneumococcal disease caused by susceptible serotypes of Streptococcus pneumoniae","Prevention of pneumococcal pneumonia"],"catalyst":""},{"name":"solifenacin succinate suspension","genericName":"solifenacin succinate suspension","slug":"solifenacin-succinate-suspension","phase":"marketed","mechanism":"Solifenacin is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder.","indications":["Overactive bladder with symptoms of urge incontinence, urgency, and frequency"],"catalyst":""}],"recentEvents":[{"date":"2024-02-06","type":"earnings","headline":"Astellas Pharma Reports Fiscal Year 2023 Results","summary":"Astellas reported a net sales increase of 5.1% to ¥1,044.9 billion for the fiscal year 2023, driven by the growth of Xtandi and Myrbetriq.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Astellas and Seagen Announce Collaboration to Develop and Commercialize Cancer Therapies","summary":"Astellas and Seagen entered into a collaboration to develop and commercialize cancer therapies, including a Phase 3-ready ADC asset.","drugName":"","sentiment":"positive"},{"date":"2023-08-25","type":"regulatory","headline":"FDA Approves Xtandi for Prostate Cancer Treatment","summary":"The FDA approved Xtandi (enzalutamide) for the treatment of prostate cancer in patients with high-risk non-metastatic castration-resistant prostate cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPZG9WQ3laZG5IZlJrTkJUVnZFTjVaMGl4QzQxS0dRaERTWmROOVdfcXM3WDZTaHlnRUpxVHpwM3BwcnhVOW5qQ3dEVHZQWmdaWHZ6eGR6Z2puMk5kak1aWTNEUTk3RS1hNDJXdkc2QkIzZHAwdUd5QjI4eEE1OF9KS3IwSjFKdjFGLXRjQml0aHVLUjJJeVFqM0w3RGpSZGRBY1pWWHI3bUd5d3drMC1jNTBSVlNfcDFJbUpUQQ?oc=5","date":"2026-04-01","type":"pipeline","source":"MarketBeat","summary":"Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume - What's Next? - MarketBeat","headline":"Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume - What's Next?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBSSnFPXzRsQWlJQ1RDWktodTl5MFJtX0NaSmJJTFNIcFBQVHltOFdNeWJIaHNFQWZUNzVpV29zRENxemFvUGwzUWhkMG81RGdURGN0LWQ0VDlWT0stWXhHRG5NOVVCYXZo?oc=5","date":"2026-04-01","type":"pipeline","source":"GuruFocus","summary":"Astellas Pharma Inc R&D Day Transcript - GuruFocus","headline":"Astellas Pharma Inc R&D Day Transcript","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOWmNYcF9pdW84d1QxWktMbUxpY3pCSUVUQVJncFNSRENtU2xFVGFpdTJKSEpuWG9xOXc0NVBQT0dPRW9kV3psQXcwZzhFaUpwZVVWUDBkeVdhSkRRY2xYTng5Q0ZfRHU0OGo1WDNzc1htRzlnMFFkMl9peVZoamxWTnRiaGZPR0NOS0pkVHVzWkVqRmhvNTdPcFBnU1V1enEzYXVibVJ5RjRKWUhEZGI2NkVWXzV2dw?oc=5","date":"2026-03-30","type":"deal","source":"MarketBeat","summary":"Astellas Pharma (OTCMKTS:ALPMY) Sets New 1-Year High - Time to Buy? - MarketBeat","headline":"Astellas Pharma (OTCMKTS:ALPMY) Sets New 1-Year High - Time to Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxORGNlNFVFNFF0ZUVXckk0VVJ5aDI4MXZpMENSY3BSR2dDNUVVQTJaMmotOG9oNVhyZ0RCLTEwMnBOcjNmTXBDU0RfTkdIYXJDSkdZbUtiNFpwVk9pMHIzVWFtMVRyYjZYNjlMdWZTSGpvNEdwSnllQUFqcjVQR21UcXljVDdBRnNzMTZKWWJRb2lhdU1IVzI4d0h6WjVOUkM2VlpJUlRlUW9aTTZLSEZj?oc=5","date":"2026-03-25","type":"pipeline","source":"Yahoo Finance","summary":"Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year? - Yahoo Finance","headline":"Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQWVkwREE4NmtWWGQtWFdEYncyaWJROWt0UzdpYlhZMUlhOTRxblE5TURONUxNLURrbjg2aFh1TzVSTzdqZ2RscnVueFVpY0ZUbTliZXVpOU5EcVcxVUx0QzB1b2hlZmR1Z3NNNGZZRnFvbG9FdUlYQWR0UHNCRnlpdGM5RzVCM0I0NGdPOGNBUzlORFR5NG5MOW43MzJtZw?oc=5","date":"2026-03-02","type":"pipeline","source":"Seeking Alpha","summary":"Astellas Pharma Inc. (ALPMY) Analyst/Investor Day - Slideshow (OTCMKTS:ALPMY) 2026-03-02 - Seeking Alpha","headline":"Astellas Pharma Inc. (ALPMY) Analyst/Investor Day - Slideshow (OTCMKTS:ALPMY) 2026-03-02","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPM0JRREUtVTJtX2swRWJMNDI0M2ZuUzZzZzczVzd0MnhJSnZJMk01UjVDR0x6NjNUVm4yNXJralFkckRIQXRTY1ZwNm9zUjZYbDVWN25iN045Mk9fMmdBUGJuNl80M094UGZ4RHRlYXdHM0l5b0IxbWtPUGMyQ2VUM2Utc3hJVnFwVE5raFNrQm1TM0t0T3lqM3IwaU9DNGdPVlpPVUlxRHVQQk5JRDgtazhkcVgzc1cxLWJMbXZzU055b0F1VmxrQjlmc28?oc=5","date":"2026-02-24","type":"pipeline","source":"Benzinga","summary":"These Analysts Boost Their Forecasts On Vir Biotechnology - Benzinga","headline":"These Analysts Boost Their Forecasts On Vir Biotechnology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5lTk9GQ0h1RllSc2NlMXY4LXFWc3Z4ajY3ZWh3RS16cmRrVy1ESUQyYnpmNmtsYXptQy1GNlNRVF9MVnNacUp0cXh0RldzUklkMlhNWml0Wm9lX19Tc3lVa09aa1BOXy1H?oc=5","date":"2026-02-04","type":"earnings","source":"GuruFocus","summary":"Q3 2026 Astellas Pharma Inc Earnings Presentation Transcript - GuruFocus","headline":"Q3 2026 Astellas Pharma Inc Earnings Presentation Transcript","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOdHpHMl9aNDJpN1UyUC1yZ0M4TE80YTB0U3NIWUNXSm9wUFM5THFIdDZYdTNxRlAyYVNVWGlIUVJLSjJNUHEyaTJJRVVjVnJHTDRCU2lCSTdDQ0dtWHd2clluTjZwVE1RNURpQXM0YUJRM2h4aUdCSk5DSXFrdlZ3VXY4TFFDeWtzQXBjM2lIQWRrSXNKRnVSRFR5NDQtc1V4SFpyS3Jn?oc=5","date":"2025-08-08","type":"earnings","source":"Seeking Alpha","summary":"Astellas Pharma Inc. 2026 Q1 - Results - Earnings Call Presentation (OTCMKTS:ALPMF) 2025-08-08 - Seeking Alpha","headline":"Astellas Pharma Inc. 2026 Q1 - Results - Earnings Call Presentation (OTCMKTS:ALPMF) 2025-08-08","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOcUY5bV9FMkh5VEpjN0xRaXFDSHBCUVdDV2ZVU1lTV0RpdzBITWlYLWFiZzNxbUpJU0szUjg0NjZ2Tm02VkNEbDZ5azBpZGMwX0t5ZjFXSkVJaEZQNFlING9BVHlqRTRRX2NUc3NvNTJrWjZ6cHN3MTRHdDJZYWVsa1hmSlBrdDIzS2VxUUVCT1NvX1dTUDk5M0pPaVlaalF4V1BXSW95dXhLXzl4NC1XUFRQcw?oc=5","date":"2025-05-29","type":"deal","source":"Stock Titan","summary":"Astellas Expands Cancer Portfolio with $1.4B Deal for Promising Gastric Cancer Drug XNW27011 - Stock Titan","headline":"Astellas Expands Cancer Portfolio with $1.4B Deal for Promising Gastric Cancer Drug XNW27011","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5ZTnRCZ0Jzall2Q0llMEtQd2tfVTZ0Q1NaWkl6cHBldFBNZHlVSWRVVjFkbF95dXFqbUNMWU1fUVN2ek9WR3ZMTFR5NjBKT1dtcU1Qd1lmMnZ4Zzg2aHRoeTZnUmU0ZHdxeV9DOUFtaDFQdkNPMTJvZ3d3?oc=5","date":"2022-10-29","type":"pipeline","source":"Zacks Investment Research","summary":"What is the current Price Target and Forecast for Astellas Pharma (ALPMY) - Zacks Investment Research","headline":"What is the current Price Target and Forecast for Astellas Pharma (ALPMY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTE9aaEI5MGY4WkxFbWVzZzhHNHNseVhfZW83Q2NpSU1ES0oyeXlBLXRDb2pRaDFvZzQ2X2ZNYXhKMTd5eWpOY0E2N3hoVU0yYUE?oc=5","date":"2021-04-18","type":"deal","source":"Stock Titan","summary":"Latest ALPMY News - Astellas Announces a Partnership with the ... - Stock Titan","headline":"Latest ALPMY News - Astellas Announces a Partnership with the ...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPRzdOek15T0FNVnRIdkhYbUl3QlQxRXFYaGs0UnkyOTU4cGhRdm5XNE43YkxLMlp0NzRJR28zUGlSZzgwaUNwdkZPN1hEM3BXOWtlR2JEUUJHeHhBcGJ1MlFiYWFHWVpxS2xHb1JZakFRYjRVTDRRQVBlakh3UE0wc2pVTlFCYUh2RVFnNVNmcG5wOHV1UHctQlczbkJvZlFIbEIyOThEZV9GUQ?oc=5","date":"2015-11-09","type":"deal","source":"RTTNews","summary":"Astellas Pharma To Acquire Ocata Therapeutics For US$8.50/shr In Cash - RTTNews","headline":"Astellas Pharma To Acquire Ocata Therapeutics For US$8.50/shr In Cash","sentiment":"neutral"}],"patents":[{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"11123331","type":"Method of Use","expiryDate":"2028-05-30","territory":"US","annualRevenue":1600000000,"genericFilings":[]},{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"11110081","type":"Method of Use","expiryDate":"2028-05-30","territory":"US","annualRevenue":1600000000,"genericFilings":[]},{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"12083103","type":"Method of Use","expiryDate":"2028-05-30","territory":"US","annualRevenue":1600000000,"genericFilings":[]},{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"10864199","type":"Method of Use","expiryDate":"2028-05-30","territory":"US","annualRevenue":1600000000,"genericFilings":[]},{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"10166190","type":"Formulation","expiryDate":"2028-05-30","territory":"US","annualRevenue":1600000000,"genericFilings":[]},{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"11419823","type":"Formulation","expiryDate":"2028-05-30","territory":"US","annualRevenue":1600000000,"genericFilings":[]},{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"9549918","type":"Formulation","expiryDate":"2028-05-30","territory":"US","annualRevenue":1600000000,"genericFilings":[]},{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"12403095","type":"Formulation","expiryDate":"2028-05-30","territory":"US","annualRevenue":1600000000,"genericFilings":[]},{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"8664239","type":"Method of Use","expiryDate":"2028-08-30","territory":"US","annualRevenue":1600000000,"genericFilings":[]},{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"8685998","type":"Formulation","expiryDate":"2028-08-30","territory":"US","annualRevenue":1600000000,"genericFilings":[]},{"drugName":"Xtandi","drugSlug":"enzalutamide","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Xtandi","drugSlug":"enzalutamide","patentNumber":"12502357","type":"Method of Use","expiryDate":"2033-09-11","territory":"US","annualRevenue":4500000000,"genericFilings":[]},{"drugName":"Xtandi","drugSlug":"enzalutamide","patentNumber":"12447128","type":"Method of Use","expiryDate":"2033-09-11","territory":"US","annualRevenue":4500000000,"genericFilings":[]},{"drugName":"Xtandi","drugSlug":"enzalutamide","patentNumber":"11839689","type":"Formulation","expiryDate":"2033-09-11","territory":"US","annualRevenue":4500000000,"genericFilings":[]},{"drugName":"Myrbetriq","drugSlug":"mirabegron","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1100000000}],"drugCount":160,"phaseCounts":{"marketed":48,"phase_1":48,"phase_2":30,"phase_3":34},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Merck & Co.","GSK"],"therapeuticFocus":["Urology","Oncology","Immunology"],"financials":null,"yahoo":{"currentPrice":16.36,"previousClose":16.38,"fiftyTwoWeekHigh":17.35,"fiftyTwoWeekLow":8.37,"fiftyTwoWeekRange":"8.37 - 17.35","fiftyDayAverage":15.46,"twoHundredDayAverage":12.47,"beta":0.15,"enterpriseValue":502031482880,"forwardPE":36.4,"priceToBook":2.64,"priceToSales":0.01,"enterpriseToRevenue":0.24,"enterpriseToEbitda":0.82,"pegRatio":0,"ebitda":608503988224,"ebitdaMargin":29.5,"freeCashflow":301368999936,"operatingCashflow":457845997568,"totalDebt":725274984448,"debtToEquity":41.1,"currentRatio":1.09,"returnOnAssets":7.4,"returnOnEquity":19.8,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":1,"targetMeanPrice":19,"targetHighPrice":19,"targetLowPrice":19,"dividendRate":0.51,"payoutRatio":1.09,"fiveYearAvgDividendYield":3.53,"exDividendDate":1759190400,"insiderHeldPercent":0,"institutionHeldPercent":0,"sharesOutstanding":1791410514,"floatShares":1791105974,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.44,"epsForward":0.45,"revenuePerShare":1150.64,"bookValue":6.21,"officers":[{"age":63,"name":"Mr. Naoki  Okamura BSc","title":"President, CEO & Director"},{"age":58,"name":"Mr. Katsuyoshi  Sugita","title":"Executive VP, Chief People Officer & Representative Director"},{"age":null,"name":"Mr. Atsushi  Kitamura","title":"Senior Executive Officer & CFO"},{"age":null,"name":"Nobue  Yasuda","title":"General Manager of Finance & Accounting Department"},{"age":null,"name":"Mr. Yoshitsugu  Shitaka Ph.D.","title":"Chief Scientific Officer & Senior Managing Executive Officer"},{"age":null,"name":"Ms. Nobuko  Kato","title":"Chief Communications & Investor Relations Officer"},{"age":null,"name":"Ms. Tatjana  Dragovic J.D.","title":"General Counsel, Chief Ethics & Compliance Officer"},{"age":null,"name":"Mr. Nobuaki  Tanaka","title":"President of Japan Commercial & Senior Corporate Executive"}],"industry":"Drug Manufacturers - General","irWebsite":"http://www.astellas.com/en/ir/","website":"https://www.astellas.com","phone":"81 3 3244 3000"}}